首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   44篇
  神经病学   44篇
  2018年   1篇
  2017年   1篇
  2016年   1篇
  2014年   1篇
  2013年   5篇
  2012年   4篇
  2011年   11篇
  2010年   10篇
  2009年   5篇
  2008年   3篇
  2007年   1篇
  2002年   1篇
排序方式: 共有44条查询结果,搜索用时 187 毫秒
1.
Genetic differences among patients suffering from Major Depression are likely to contribute to interindividual differences in medication treatment response. Thus, the identification of gene variants affecting drug response is needed in order to be able to predict response to psychopharmacological drugs. This study analyzed a possible association of the common A644G single nucleotide polymorphism (SNP) within intron 13 of the monoamine oxidase B (MAOB) gene with antidepressant treatment response. The study population consisted of n = 102 patients with major depression (criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; DSM-IV) participating in a randomized double-blind controlled clinical trial, conducted at 50 centers in Germany, comparing the efficacy of mirtazapine and paroxetine during 6 weeks of treatment. Overall, female patients homozygous for the A-allele had a significantly faster and more pronounced antidepressant treatment response than AG/GG-carriers. In paroxetine-treated females these differences remained statistically significant. In mirtazapine-treated females homozygous for the A-allele compared to AG/GG-carriers, HAMD-17 scores during the study period were constantly and markedly lower, but not statistically different. In males, we found no association between the MAOB A644G intron 13 SNP and antidepressant treatment response. Our data provide first suggestive evidence that the MAOB A644G SNP is involved in the outcome of treatment with mirtazapine or paroxetine in females with major depression. To confirm the role of the MAOB A644G gene variant in antidepressant treatment response, independent replications are needed. If replicated, the MAOB A644G polymorphism could be considered useful for prospective confirmatory pharmacogenetic trials in patients with major depression.  相似文献
2.
Excessive free radical production leading to oxidative stress may be involved in the pathophysiology of schizophrenia. Determination of total antioxidant status (TAS) provides an index of the sum of activities of all antioxidants. However, there have been few systematic studies to examine the relationship between TAS levels and psychopathology in first-episode and drug-naive patients with schizophrenia.TAS levels were determined in the plasma of 60 never-medicated first-episode patients with schizophrenia and 68 healthy control subjects. The schizophrenia symptomatology and the depressive symptoms were assessed by the positive and negative syndrome scale (PANSS) and the Hamilton rating scale for depression (HAMD). The results showed that TAS levels were significantly lower in first-episode patients with schizophrenia than in healthy control subjects (159.8 ± 45.8 U/ml vs 211.4 ± 46.8 U/ml, F = 39.5, df = 1, 126, p < 0.001). A trend toward significant inverse correlation between TAS levels and PANSS negative subscore was observed (r = 0.25, df = 60, p = 0.06). Our results suggest that oxidative stress occurs in an early course of schizophrenia and may have an important role in pathogenesis and perhaps, negative symptomatology of schizophrenia.  相似文献
3.
肌萎缩侧索硬化症患者抑郁状况调查及药物干预效果   总被引:1,自引:0,他引:1  
目的调查肌萎缩侧索硬化症(ALS)患者抑郁发生率并观察药物干预效果。方法采用汉密尔顿抑郁量表(HAMD)对64例ALS患者进行测评,对伴有抑郁的不同性别、年龄及文化程度的患者进行评分比较,并对其中30例患者行抗抑郁药物干预,1个月后再进行量表测定。结果 64例ALS患者中有60例(93.4%)存在不同程度的抑郁,不同性别及年龄组的ALS患者HAMD得分无显著差异(P>0.05),但文化程度较高的ALS患者抑郁程度显著高于文化程度较低的ALS患者(P<0.01),30例伴有抑郁的ALS患者在接受抗抑郁药物干预1个月后其抑郁程度明显减轻(P<0.01)。结论绝大多数ALS患者合并抑郁,合理药物干预能有效改善ALS患者的抑郁状态。  相似文献
4.
Existing therapies for major depressive disorder (MDD) have either limited efficacy and/or poor tolerability. The present study examined the effects of duloxetine, a potent and balanced dual reuptake inhibitor of serotonin (5-HT) and norepinephrine (NE), in patients with MDD. Adult patients (N=267) with MDD were randomly assigned to receive duloxetine (60 mg/day) or placebo in this 9-week, multi-center, double-blind, parallel-group clinical trial. Efficacy was evaluated using the 17-item Hamilton Depression Rating Scale (HAMD17), Visual Analog Scales (VAS) for pain, Clinical Global Impression of Severity (CGI-S), Patient's Global Impression of Improvement (PGI-I), and Quality of Life in Depression Scale (QLDS). Safety was evaluated by assessing discontinuation rates, adverse event rates, vital signs, and laboratory tests. Duloxetine (60 mg QD) significantly reduced the HAMD17 total score compared with placebo at the end of 9-week therapy. Estimated probabilities of response and remission were 65 and 43%, respectively, for duloxetine compared with 42 and 28% for placebo. Duloxetine also reduced overall pain, back pain, shoulder pain and time in pain while awake significantly more than placebo. Global measures of improvement, including PGI-I and QLDS, were significantly improved by duloxetine compared with placebo. Discontinuations due to adverse events were more frequent for duloxetine-treated patients (12.5%) than for placebo-treated patients (4.3%). Nausea, dry mouth, dizziness, and constipation were more frequent for duloxetine than placebo. There was no significant incidence of hypertension, nor any other safety issues. Duloxetine 60 mg administered once daily appears to be a safe and effective treatment for MDD.  相似文献
5.
目的 探讨心理康复配合头针、腹针治疗卒中后抑郁(PSD)的临床效果.方法 将60例脑卒中后抑郁患者随机分为心理康复组和联合治疗组各30例.2组均予以心理康复治疗,联合治疗组同时给予头针、薄氏腹针治疗,治疗时间为8周.2组均在治疗前和治疗后参照汉密尔顿抑郁量表(HAMD)进行评定.结果 联合治疗组抑郁症状改善明显优于心理康复组,差异均有统计学意义(P<0.05).结论 心理康复配合头针、薄氏腹针治疗可明显缓解和消除PSD症状,有助于神经功能恢复.  相似文献
6.
目的:探索单相抑郁、双相 I 型和双相 II 型抑郁患者情感气质特征的差异及其与抗抑郁治疗反应的关系。方法收集广州医科大学附属脑科医院和暨南大学第一附属医院的住院和门诊患者,包括332例单相抑郁患者、116例双相I 型患者和152例双相 II 型患者,所有患者均处于重性抑郁发作期。在为期6周的半自然临床试验中,所有患者均接受抗抑郁药治疗,完成情感气质问卷中文版(TEMPS - A)和汉密尔顿抑郁量表17项版(HAMD -17)评定。比较治疗4、6周末不同气质类型为主导气质患者 HAMD -17评分减分率。结果双相 I 型患者旺盛情感气质评分高于单相抑郁患者和双相 II 型患者[(9.91±4.53)分 vs.(8.20±4.34)分 vs.(8.53±4.14),F =6.562,P =0.002];而双相 II 型患者环性气质评分高于单相抑郁患者[(10.05±5.02)分 vs.(7.47±5.22)分,F =12.89,P <0.01]。治疗6周后,情感旺盛气质主导组 HAMD -17评分减分率高于情感旺盛气质非主导组(F =6.44,P =0.011)。结论单双相抑郁患者的情感旺盛气质和环性气质的特征有所差异,旺盛情感气质可能可以作为处于重性抑郁发作期的情感障碍患者抗抑郁治疗反应的预测因子。  相似文献
7.
目的 探讨阿尔茨海默病(AD)与血清脑源性神经营养因子(BDNF)水平的关系。方法 采用酶联免疫吸附法对46例AD患者(研究组)和44例正常对照者(对照组)的外周血清进行BDNF水平检测。所有受试者均进行简易精神状态量表(MMSE)、Hachinski缺血指数(HIS)及汉密尔顿抑郁量表(HAMD)评定,AD患者用临床痴呆评定量表(CDR)进行痴呆严重程度分级。结果 研究组血清BDNF水平低于对照组(P〈0.01)。研究组轻度、中度与重度AD患者血清BDNF水平均低于对照组(P〈0.01),重度AD血清BDNF水平低于轻度AD(P〈0.05)。研究组血清BDNF水平与年龄、病程呈负相关(P〈0.01),与MMSE评分呈正相关(P〈0.01)。结论 AD患者存在血清BDNF水平降低,且与其年龄、病程及痴呆程度显著相关。  相似文献
8.
Taking into consideration the previous evidence of revealing the relationship of early life adversity, major depressive disorder (MDD), and stress-linked immunological changes, we recruited 22 MDD patients with childhood trauma exposures (CTE), 21 MDD patients without CTE, and 22 healthy controls without CTE, and then utilized a novel cytokine antibody array methodology to detect potential biomarkers underlying MDD in 120 peripheral cytokines and to evaluate the effect of CTE on cytokine changes in MDD patients. Although 13 cytokines were identified with highly significant differences in expressions between MDD patients and normal controls, this relationship was significantly attenuated and no longer significant after consideration of the effect of CTE in MDD patients. Depressed individuals with CTE (TD patients) were more likely to have higher peripheral levels of those cytokines. Severity of depression was associated with plasma levels of certain increased cytokines; meanwhile, the increased cytokines led to a proper separation of TD patients from normal controls during clustering analyses. Our research outcomes add great strength to the relationship between depression and cytokine changes and suggest that childhood trauma may play a vital role in the co-appearance of cytokine changes and depression.  相似文献
9.
目的探讨度洛西汀对恶性肿瘤患者伴发抑郁障碍的临床疗效及安全性。方法60例肿瘤伴发抑郁的患者,随机分为两组,每组30例,两组患者均接受常规抗肿瘤治疗,研究组在此基础上联合度洛西汀治疗,观察8周。于治疗前及治疗2周、4周及8周末采用汉密尔顿抑郁量表评定抑郁情绪,副反应量表评定不良反应。结果治疗8周末研究组抑郁情绪改善率为76.7%,未治疗组为26.7%,研究组显著高于未治疗组(P〈O.01);研究组汉密尔顿量表评分较未治疗组显著下降(P〈O.05);两组不良反应无差异性。结论度洛西汀治疗肿瘤患者伴发抑郁障碍效果显著,安全性高。  相似文献
10.
目的 评估超低频经颅磁刺激对抑郁症患者的疗效.方法 在某精神卫生中心心身疾病科选择符合〈国际疾病分类(第10版)〉(ICD-10)抑郁发作诊断标准的住院病人共100人,采用简单随机法分为药物联合超低频经颅磁刺激治疗组(研究组)与单纯药物治疗组(对照组).两组均使用帕罗西汀治疗,研究组联合超低频经颅磁刺激治疗,对照组给予"伪治疗".治疗前和治疗4周分别对所有研究对象进行汉密尔顿抑郁量表(HAMD-17)评定,计算两次量表分差得到减分数.结果 治疗后,研究组HAMD平均得分(8.33±0.76)分,对照组平均得分(7.15±0.62)分,两组间差异有统计学意义(P〈0.05);研究组平均药物用量为31.18mg/d,对照组为22.14mg/d,两者差异有统计学意义(P〈0.05);研究组HAMD平均减分数为10.82分,对照组为11.92分,两者差异无统计学意义(P〉0.05).结论 药物联合超低频经颅磁刺激对抑郁症疗效差于单纯药物治疗,且可能增加抗抑郁剂用量.  相似文献
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号